Search

Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies

Protecting Humans & Animals | COVID-19 | Boehringer Ingelheim US

Read more on Boehringer Ingelheim's commitment to protecting both humans and animals during the COVID-19 pandemic.

Partnering for Innovative Pet Therapeutics

Flying animals to safety with Greater Good Charities

Watch as Julie Ryan-Johnson volunteers to take care of animals being brought to new homes following the Maui wildfires.

Schizophrenia: Trial Results Show Advance in Cognition | BI US

Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary endpoint.

Boehringer Ingelheim and Yale Clinical and Translational Research Accelerator collaborate to explore potential benefits of digital health technologies for adults with heart failure

Making Toys for Shelter Animals | Boehringer Ingelheim US

Find out how nearly 400 Boehringer Ingelheim employees came together to make toys out of donated t-shirts for animals living in shelters across the USA.

Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program

Translating Human Pharma Science into Animal Health Innovation

Megan Grether shares her perspectives on the importance of translating human pharma science to accelerate innovation in animal health

Innovation in CNS Disease Research

Prioritizing mental health and well-being today and every day

Prioritizing Mental Health and Well-being Today and Everyday

Employees compassionately help local communities with country-wide food drive

Coming together to bring food to people in need

Boehringer Ingelheim’s Carine Boustany Appointed to BIO Board

Yew Looi Liew Named President of U.S. Human Pharma for Boehringer Ingelheim Pharmaceuticals, Inc.

COVID-19: Boehringer Ingelheim steps up effort with Global Support Program

2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical

Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer

Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.

BI & Gubra Join Forces to Identify Peptides | Boehringer Ingelheim US

BI & Gubra announce research & licensing agreement focused on the identification & validation of targets & peptide compounds for the treatment of obesity.

Country Management Committee: A Message | Boehringer Ingelheim US

Click here to read a statement from Boehringer Ingelheim on the tragic events in Uvalde, TX and how BI Cares is supporting victims and families.

Looking Ahead at Recruitment in the Biopharma Industry

Partnering Interests

Annual Declaration of Boehringer Ingelheim Corporation’s compliance with its Comprehensive Compliance Program.

Boehringer Ingelheim Animal Health Appoints Randolph Legg to Lead U.S. Commercial Business

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers